In the fourth quarter alone, Garcia said approximately 9,400 patients utilized CapsoCam Plus, up from about 8,374 in the prior-year period, representing 12% year-over-year growth. Garcia cited increasing physician awareness, clinical utility, and ease of workflow integration as drivers. He also pointed to reimbursement support across private practices and hospital systems.For full-year 2025, Wang reported approximately 15% year-over-year revenue growth and a 21% increase in new account generation, which man ...

CapsoVision (NasdaqCM:CV) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Company ParticipantsDavid Garcia - SVP of FinanceJohnny Wang - President and CEOLeigh Salvo - Investor RelationsConference Call ParticipantsBruce Jackson - Senior AnalystKyle Bowser - Senior Research AnalystOperatorLadies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the CapsoVision Fourth Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background ...

CapsoVision (NasdaqCM:CV) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Company ParticipantsDavid Garcia - SVP of FinanceJohnny Wang - President and CEOLeigh Salvo - Investor RelationsConference Call ParticipantsBruce Jackson - Senior AnalystKyle Bowser - Senior Research AnalystOperatorLadies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the CapsoVision fourth quarter 2025 earnings conference call. All lines have been placed on mute to prevent any background ...

CapsoVision (NasdaqCM:CV) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Speaker5Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the CapsoVision fourth quarter 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If ...

CapsoVision (NasdaqCM:CV) FY Conference March 23, 2026 01:30 PM ET Company ParticipantsDavid Garcia - Senior VP of FinanceDoug Atkinson - Senior VP of Global SalesJohnny Wang - Co-Founder, President, and CEOConference Call ParticipantsKyle Bauser - Senior Research AnalystKyle BauserMy name is Kyle Bauser, and I'm a Senior Research Analyst with Roth covering the medical device sector. Today we have CapsoVision here for a fireside chat. We are joined by Johnny Wang, Co-founder, President, and CEO, David Garci ...

Core Insights - CapsoVision, Inc. has submitted a 510(k) application to the FDA for an AI-based reading feature for its CapsoCam Plus capsule endoscopy system, aimed at improving diagnostic accuracy and workflow efficiency for clinicians [1][2] - The company believes that the integration of advanced imaging and AI models positions CapsoCam Plus as a next-generation solution for small bowel diagnostics [2] - Following the announcement, CapsoVision's shares declined by 7.7%, despite a significant increase of 205.4% over the past six months [3][8] Company Developments - The AI feature is designed to enhance the image review process, addressing lengthy review times and variability in diagnosing gastrointestinal diseases [4] - CapsoVision's market capitalization currently stands at $580.39 million [5] - The AI-assisted CapsoCam Plus aims to provide clearer images of the digestive tract, reducing the chance of missed problems and improving the experience for both doctors and patients [9][10] Technological Advancements - The AI-assisted reading module utilizes an in-house image dataset to improve diagnostic accuracy while reducing clinician workload [10] - CapsoVision's fully cloud-based system eliminates the need for on-site servers, lowering costs and maintenance requirements for GI practices [11] Industry Outlook - The capsule endoscopy market is projected to reach $479.13 million by 2025, with a CAGR of 7.95% through 2034, driven by the adoption of minimally invasive diagnostics and AI-enabled image interpretation [12] - Factors such as increasing use of capsule endoscopy in pediatric and geriatric populations and growing clinical trials for oncology screening are expected to contribute to market growth [12] Future Prospects - CapsoVision is also pursuing FDA Breakthrough Device Designation for its CapsoCam UGI capsule, aimed at early detection of pancreatic ductal adenocarcinoma [13] - The company is developing CapsoCam Colon, which will utilize advanced AI for non-invasive imaging of the colon [13]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $3.5 million, reflecting a 19% increase compared to Q3 2024, driven by an increase in the number of CapsoCam Plus capsules sold [15] - Gross margin was 54% for the quarter, consistent with expectations as the company scales [15] - Net loss for Q3 2025 was $7.9 million, compared to a net loss of $5.8 million in Q3 2024 [16] - Cash and equivalents at the end of the quarter were $17.8 million, an increase from $1.1 million at June 30, 2025, following the completion of the IPO [16] Business Line Data and Key Metrics Changes - CapsoCam Plus has been used by over 151,000 patients, with approximately 8,336 patients using the system in Q3 2025, representing a 20% year-over-year growth [11] - New account generation grew by 31% in Q3 2025 compared to the same quarter in 2024, indicating strong physician adoption [14] - A 24% increase in GI clinics and mega GI groups was noted in Q3 2025 over the same quarter last year [14] Market Data and Key Metrics Changes - The company is gaining traction in hospitals and GPOs, with a 26% increase in hospital system customers over the prior year [14] - The U.S. direct sales team included 26 representatives, supported by seven regional sales managers and trainers as of September 30, 2025 [12] Company Strategy and Development Direction - The long-term vision is to deliver an ingestible capsule that can screen for multiple cancers in a single non-invasive procedure powered by advanced imaging and AI [4] - The company is investing in AI to improve existing products and plans to submit an application to the FDA by year-end 2025 for AI technology incorporation into CapsoCam Plus [5][6] - CapsoVision is pursuing Breakthrough Device Designation for its non-invasive capsule endoscopy system to enable earlier detection of pancreatic ductal adenocarcinoma [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum across the business, highlighting commercial growth, pipeline expansion, and advancements in AI-assisted diagnostics [18] - The application for Breakthrough Device Designation reflects the urgent need for early detection of pancreatic cancer and the promise of the company's technology [18] - The company is strengthening its leadership team and executing a clear growth plan following a successful IPO [19] Other Important Information - The company has a development agreement with Canon Incorporated to design next-generation CMOS imaging sensors, marking a key step in advancing its innovation pipeline [16] - R&D expenses related to the Canon agreement were $1.6 million for Q3 2025, considered a one-time charge [15] Q&A Session Summary Question: Impact of AI feature submission on other milestones - Management indicated that the FDA review typically takes three to six months, so the approval should be available in the second half of the year [22] Question: Operating expenses related to Canon agreement - The $1.6 million expense for R&D for Canon is a one-time charge, and future core R&D expenses should be lower [23] Question: Clinical data for breakthrough designation application - A small feasibility study conducted six years ago showed promising results, with two out of 20 subjects diagnosed with cancer [28] Question: Timeline for Canon CMOS sensor - The pivotal study for pancreatic cancer will proceed without waiting for the Canon sensor, which is expected to be ready in 2026 [35] Question: Commercial organization headcount - The current sales team will be maintained, with plans to add two additional territories in 2026 as needed [36]

Transforming GI Detection and Screening Our long-term, lifesaving vision is an ingestible capsule that, in a single, convenient, and noninvasive procedure, screens for multiple cancers— esophageal, gastric, pancreatic, liver, and colon—at early and still precancerous stages, using AI to analyze thousands of images captured in the GI tract. CapsoVision: Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that reflect our current expectations and views ...

Financial Data and Key Metrics Changes - For Q2 2025, total revenue was $3.3 million, reflecting a 17% growth compared to 2024, driven by an increase in the number of CapsoCam Plus capsules sold [23][24] - Gross margin for the quarter was 55%, consistent with expectations as the company scales [24] - Net loss was $4.6 million for Q2 2025, compared to a net loss of $5.3 million in Q2 2024 [24] Business Line Data and Key Metrics Changes - As of June 30, 2025, CapsoCam Plus for small bowel screening has been used by over 143,000 patients, with approximately 7,900 patients using the system in 2025, representing a year-over-year growth of 17% [19][20] - New accounts grew by 75% in 2025 compared to the same quarter in 2024, indicating continued physician adoption [22] - A 46% increase in GI clinics and mega GI groups was observed in 2025 over the same quarter last year [22] Market Data and Key Metrics Changes - The market potential for the CapsuleCam colon is estimated to exceed $1 billion, targeting patients at higher risk for colonoscopy-related complications [12] - The company is expanding its pipeline to address other parts of the GI tract, including pancreatic and esophageal varices screening, which represents a significant market opportunity [17][18] Company Strategy and Development Direction - The company aims to leverage its existing sales infrastructure to expand into additional indications, creating cross-sell opportunities without significant increases in headcount [22] - The development pipeline includes the submission of an AI module for CapsoCam Plus to the FDA by late September or early October, which is expected to enhance diagnostic capabilities [10][27] - The company plans to initiate pivotal studies for esophageal varices screening in 2026, further broadening its market opportunity [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's technology, strategy, and team to execute on growth opportunities, particularly in the small bowel market and the integration of AI [27] - The company anticipates stronger sales in Q3 and expects Q4 sales to be historically the highest due to seasonal trends [26] Other Important Information - The company completed its initial public offering on July 3, 2025, receiving total net proceeds of $23.4 million [25] - A development agreement with Canon was announced to design and evaluate next-generation CMOS image sensors, valued at approximately $4.1 million [26] Q&A Session Summary Question: Clarification on colon launch plans - The plan is for the second-generation device, not the initial device submitted [30][31] Question: Timing for the second-generation colon capsule - The submission for the second-generation device is planned for the first quarter, following the first approval [34][35] Question: Details on the Canon arrangement - The agreement includes an upfront payment of $1 million and spans a couple of years, with deliverables tied to the final engineering design [37] Question: Cash burn in the quarter and expectations for the year - Cash burn was around $11.5 million, with expectations of approximately $20 million for the year [40] Question: Timeline for AI feature submission and market receptivity - The AI module is planned for submission in September, with a launch expected next year; doctors are already aware of the feature and receptive to it [42][44] Question: Advantages of in-house AI development - The company has complete control over its AI development, which provides a significant advantage compared to relying on external partners [46]

Core Insights - CapsoVision, Inc. reported a total revenue of $3.3 million for Q2 2025, marking a 17% increase compared to Q2 2024, primarily driven by increased sales of CapsoCam Plus capsules [6][9] - The company successfully completed its IPO in July 2025, raising net proceeds of approximately $23.4 million, which will be used to accelerate growth and expand into new indications [3][7][9] - Management highlighted the importance of obtaining FDA 510(k) approval for the AI module in CapsoCam Plus and the continued development of CapsoCam Colon as key growth drivers [4][5] Financial Performance - Total revenue for Q2 2025 was $3.3 million, a 17% increase from $2.8 million in Q2 2024 [6][14] - Gross profit increased to $1.8 million, up 14% from $1.6 million in Q2 2024, with a gross margin of 55% [6][14] - Operating expenses decreased to $6.5 million, down $0.4 million from Q2 2024, mainly due to reduced expenses related to clinical trials [7][14] Operational Highlights - New accounts grew by 75% in Q2 2025 compared to the same quarter in 2024 [9] - CapsoCam Plus has been utilized by over 143,000 patients as of June 30, 2025 [9] - The company submitted a 510(k) notification to the FDA for CapsoCam Colon in June 2025 [9] Future Outlook - The company aims to enhance accuracy and ease physician workload through the integration of AI in its products [4] - CapsoVision plans to advance programs targeting pancreatic cancer and esophageal varices, leveraging its panoramic imaging technology [4][5]